SecBot SecBot
8-K ·Filed Apr 13, 2026

CGON

CG Oncology, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago SEC0001193125-26-152044
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The CFO appointment is a routine executive transition following an interim period. While the $5 million in equity grants represents a significant compensation package, the appointment itself is expected to ensure leadership continuity rather than signal a strategic shift. Traders should monitor the company's progress toward product commercialization, as this triggers vesting of a significant portion of DeTore's performance stock units.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$67.70
T+0 close · Apr 13, 2026 · via day close
Latest settled
+3.10%
T+60 · $69.80
Vs SPY
−5.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $67.70entry
  2. T+1 · 7mo ago −0.62%α −1.83% · $67.28
  3. T+5 · 7mo ago +3.99%α +0.69% · $70.40
  4. T+20 · 6mo ago +2.39%α −5.34% · $69.32
  5. T+60 · 4mo ago +3.10%α −5.82% · $69.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology appointed Jim DeTore as Chief Financial Officer, effective April 13, 2026. The appointment follows his interim role since November 2025 and includes a formal employment agreement with a $520,000 annual base salary and $5 million in initial equity awards.

Key Facts

  • Jim DeTore was formally appointed Chief Financial Officer effective April 13, 2026
  • DeTore had been serving as Interim Principal Financial and Accounting Officer since November 2025
  • He receives a $520,000 annual base salary and is eligible for a 45% target annual bonus
  • He received an initial stock option grant valued at $4 million and a performance stock unit award valued at $1 million
  • The PSU award vests 30% upon first U.S. commercial sale of the company's first approved product and 70% upon achievement of positive operating cash flow for two consecutive quarters post-launch

Financial Impact

Initial equity awards totaling $5 million ($4 million stock options, $1 million in PSUs) and $520,000 annual base salary

compensationequity grantsoperating expenses

Risk Factors

  • Potential for executive turnover if performance expectations are not met
  • Dilution from the $5 million in new equity grants

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-152044
Document: ck0001991792-20260413.htm0001193125-26-152044
Document: 0001193125-26-152044-index-headers.html0001193125-26-152044
Document: 0001193125-26-152044-index.html0001193125-26-152044
Document: 0001193125-26-152044.txt0001193125-26-152044

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026